Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046299 | 0.93 | L3MBTL1 (0.44) | KCNA5CYP3A4EPHX1TSHRLMNA | |
| SCHEMBL7047980 | 0.92 | TBXA2R (0.37) | KCNA5CYP3A4MAPTSLC1A3SLC1A1 | |
| SCHEMBL7045334 | 0.90 | CYP1A2 (0.42) | KCNA5CYP3A4MAPTTSHRALDH1A1 | |
| SCHEMBL7186575 | 0.89 | CACNA1H (0.37) | KCNA5MAPTSLC1A3SLC1A1LMNA | |
| SCHEMBL7049297 | 0.89 | HPGD (0.40) | KCNA5GAACYP3A4MAPTSLC1A3 | |
| SCHEMBL7044845 | 0.88 | KCNA5 (0.39) | KCNA5CYP3A4SLC1A3SLC1A1LMNA | |
| SCHEMBL7047185 | 0.84 | CTSL (0.37) | CYP3A4TSHRSLC1A3SLC1A1ALDH1A1 | |
| SCHEMBL6063739 | 0.80 | IDO1 (0.35) | KCNA5CYP3A4TSHRSLC1A3SLC1A1 | |
| SCHEMBL7183275 | 0.80 | MEN1 (0.38) | L3MBTL1POLB | |
| SCHEMBL6465943 | 0.79 | ANPEP (0.44) | KCNA5CYP3A4MAPTSLC1A3SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | KCNA5 4351/4885GAA 292/4885CYP3A4 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.